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Abstract 
Background: Western dietary pattern is included among the environmental dietary factors involved in the patho-
genesis of psoriasis. Nutritional data collection methods and gender differences might affect the association between 
diet and psoriasis. The 7-day food records is considered the “gold standard” of self-administered food frequency ques-
tionnaires. In this study, we evaluated the differences in the dietary intake, anthropometric measurements and cardio-
metabolic risk profile in a group of psoriatic patients compared with an age and Body Mass Index (BMI)-matched 
control group. In addition, in the group of psoriatic patients we investigated the association between the dietary 
intake and clinical severity of psoriasis.
Methods: Cross-sectional case control observational study. A total of 82 adult males, 41 treatment-naïve patients 
with psoriasis and 41 healthy subjects matched for age and BMI were included in the study. The clinical severity of 
psoriasis was by assessed by Psoriasis Area and Severity Index (PASI) score. The dietary interview data were collected 
by a 7-day food records. Anthropometric measures, glucose and lipid profile, liver function tests and C-reactive pro-
tein levels were measured. Homeostasis Model Assessment of Insulin Resistance (HoMA-IR), Visceral Adiposity Index 
(VAI) and the Fatty Liver Index (FLI) were calculated.
Results: Psoriatic patients consumed a higher percentage of total and simple carbohydrates, total fat, polyunsatu-
rated fatty acid (PUFA) and n-6/n-3 PUFAs ratio, and cholesterol, while the consumption of protein, complex carbo-
hydrates, monounsaturated fatty acid (MUFA), n-3 PUFA and fiber was lower than in the control group. In addition, 
psoriatic patients presented altered anthropometric measurements, glucose and lipid profile, liver function tests, and 
elevated values of HoMA-IR, VAI and FLI. PASI score well correlated with anthropometric measures, glucose and lipid 
profile, liver function tests, cardio-metabolic indices, and the dietary components, except for protein and total car-
bohydrates. At logistic regression analysis between PASI score and MUFA, MetS presence was well predicted only by 
higher PASI score (OR = 1.794; p = 0.002; CI 1.242–2.591). At multiple regression analysis, MUFA was the best predictor 
of PASI score (r2 = 0.387, β = −0.635, t = −5.127, p < 0.001).
Conclusion: Differences in dietary intake were observed in adult male psoriatic patients compared with the con-
trols. These differences were associated to the severity of the psoriasis and cardio-metabolic risk. FLI represented an 
early indicator of the cardio-metabolic risk profile in psoriatic patients, and dietary MUFA were major predictor of 
the clinical severity of psoriasis, while the association between psoriasis and metabolic syndrome appeared to be 
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Background
Psoriasis is a common chronic inflammatory skin dis-
ease associated with obesity and serious comorbidities, 
such as type 2 diabetes mellitus, hypertension, metabolic 
syndrome [1], and hepatic steatosis (HS) [2], a major fea-
ture associated with the non-alcoholic fat liver disease 
(NAFLD) and the hepatic manifestation of metabolic 
syndrome [3]. It has been speculated that visceral obe-
sity, insulin resistance and the release of inflammatory 
cytokines, may play a role in this association [4, 5].
The incidence of chronic inflammatory diseases is 
increased in Western countries over the past few decades 
[6]. In addition, males and females exhibit substantial 
differences in their eating behaviors in terms of energy 
intake, food consumption and nutrients intake [7, 8]. 
In particular, besides basic gender differences in weight 
concern and body self-perception, adults males consume 
more energy, saturated fat acid (SFA), and cholesterol 
but less complex carbohydrates and fibre than females. 
Specific macronutrient, such as simple carbohydrates, 
SFA and n-6 polyunsaturated fatty acid (n-6 PUFA) may 
contribute to a proinflammatory state, while others, 
including fiber, monounsaturated fat acid (MUFA), n-3 
polyunsaturated fatty acid (n-3 PUFA), are associated 
with reduced levels of inflammatory [9].
The temporal sequence of the bidirectional relation-
ships between inflammatory state induced by the West-
ern dietary pattern, metabolic syndrome and psoriasis 
is still debated [10]. Indeed, the diet is included among 
risk factors for psoriasis [11] and dietary modifications 
have been reported to modulate the clinical course 
of the disease [12]. In particular, a reduced consump-
tion of specific food items, such as black coffee, black 
tea, chocolate, yerba mate, pepper, smoked foods, beef 
and monosodium glutamate as flavor enhancer, and an 
increased consumption of foods rich in beta carotene 
have been strongly recommended, along with the sus-
pension of alcoholic drinks and tobacco [13]. A protec-
tive effect of an energy-restricted diet enriched in n-3 
PUFA on metabolic markers and clinical outcome in 
obese patients with psoriasis has been recently dem-
onstrated [14]. Moreover, adherence to Mediterranean 
diet and in particular the consumption of some food 
items, such as extra-virgin olive oil (EVOO), the main 
source of MUFA, have been linked to the severity of the 
disease in a group of psoriatic patients of both gender 
[15].
Observational studies describing the association 
between diet and psoriasis have been commonly per-
formed including psoriatic patients of both gender and 
using self-report methods. To date, a careful evaluation 
of dietary intake using the 7-day food records, considered 
the “gold standard” of self-administered food frequency 
questionnaires [16, 17], has not been yet provided, and 
no studies evaluating separately the dietary intake in 
males and females with psoriasis are available. Moreo-
ver, the large majority of studies have included patients 
in treatment with anti-psoriatic agents, such as biolog-
ics, systemic corticosteroids or methotrexate, which may 
have interfered with anthropometric measures and blood 
glucose and lipid profile [18]. Finally, in the setting of the 
inflammation-related insulin resistance, the association 
between psoriasis and other cardio-metabolic risk indi-
ces, such as the Visceral Adiposity Index (VAI), a gender-
specific indicator of adipose distribution and dysfunction 
[19], and the Fatty Liver Index (FLI), as an accurate pre-
dictor of HS [20] has not yet evaluated.
Aim of the present study is to compare the dietary 
intake (using a 7-day food records), anthropometric 
measurements and cardio-metabolic risk profile (defined 
by the Homeostasis Model Assessment of Insulin Resist-
ance (HoMA-IR), VAI and FLI) between male psoriatic 
patients and healthy control subjects matched by age and 
Body Mass Index (BMI). In addition, in the group of pso-
riatic patients we investigated the association between 
the dietary intake and clinical severity of psoriasis to evi-
dence a possible involvement of the diet-induced proin-
flammatory state as adjunctive mechanism increasing the 
inflammation milieu of psoriatic patients.
Methods
Design and setting
This is a cross-sectional case–control observational study 
carried out at the Department of Clinical Medicine and 
Surgery of the University of Naples Federico II (Italy). The 
work has been carried out in accordance with the Code 
of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans, and it has 
been approved by the Ethical Committee of the Univer-
sity of Naples “Federico II” Medical School. The purpose 
of the protocol was explained to both the patients and the 
controls, and written informed consent was obtained.
The study was conducted without support from the 
pharmaceutical industry.
independent of MUFA intake. The low MUFA consumption might act as a possible adjunctive mechanism in increas-
ing the inflammation milieu of psoriatic patients.
Keywords: Environmental dietary factor, 7-day food records, PASI, HoMA-IR, VAI, FLI, MUFA
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Population study
The study has been conducted on 41 adult treatment-
naïve patients out of 254 unselected Caucasian subjects 
of both gender affected by psoriasis attending the Psoria-
sis Care Center of the Outpatient Clinic of the Section of 
Dermatology, University of Naples Federico II from July 
2013 to July 2014. In order to improve the power of the 
study, we increased the homogeneity of the patient sam-
ple by including treatment-naïve adult male patients only. 
Patients were excluded from the study if they (1) were 
females (122 patients); (2) had a diagnosis of psoriasis 
lasting >6  months or were receiving any systemic treat-
ment for psoriasis including acitretin, ciclosporin, meth-
otrexate, phototherapy or biologics for at least 3 months 
(48 patients); (3) had a diagnosis of pustular (2 patients), 
erythrodermic (1 patient) or arthropathic psoriasis (13 
patients); (4) had received any drug therapy known to 
affect carbohydrate or lipid metabolism during the previ-
ous 6 months (6 patients); (5) had a history of excessive 
alcohol use (2 patients); (6) were current smokers (15 
patients); (7) neoplastic, metabolic, hepatic, and cardio-
vascular disorder or other concurrent medical illness (i.e. 
renal disease, and malabsorptive disorders) (4 patients).
Forty-one healthy subjects were chosen as controls 
among hospital volunteers and employees from the same 
geographical area. Controls were matched by age and 
BMI and had comparable education, employment, mari-
tal status, or participation in physical activity as the study 
group. Exercise pattern and type were noted by asking 
orally.
The Psoriasis Area and Severity Index (PASI) score is 
a validated and widely used tool for measuring psoriasis 
severity [21]. The scale evaluates four areas of the body 
(head/neck, upper limbs, trunk, and lower limbs) for ery-
thema, scaliness and thickness of psoriatic plaques. The 
PASI score can range from 0 to 72, with higher scores 
indicating greater severity. To prevent rate biases the der-
matologists who evaluated the PASI score were blinded 
to the design of the study.
Dietary assessment
These data were carried out during a face-to-face inter-
view between the patient and a certified nutritionist. The 
dietary interview allowed to quantify foods and drinks 
by using a photographic food atlas (≈1000 photographs) 
of known portion sizes to ensure accurate completion 
of the records. Moreover, dietary data, including bever-
age intakes and alcohol consumption, were collected by 
a 7-day food records. The subjects returned the records 
to the nutritionist who asked supplemental questions if 
necessary. Data were stored and processed using a com-
mercial software (Terapia Alimentare Dietosystem® DS-
Medica, http://www.dsmedica.info). Considering the 
quantities and qualities of foods consumed, this database, 
that included about 300 food items, was able to calculate 
not only the daily caloric intake but also the quantities 
of macronutrients: protein; total, complex and simple 
carbohydrates; total fat, SFA, MUFA, PUFA (n-6 PUFA, 
n-3 PUFA and n-6/n-3 PUFAs ratio); cholesterol and fib-
ers. The dietary macronutrient composition was drawn 
by the tables of food composition and recommended 
dietary intakes of the BDA (Food Composition Database 
for Epidemiological Studies in Italy, European Institute of 
Oncology, http://www.bda-ieo.it/).
Anthropometric measurements
All anthropometric measurements were taken with sub-
jects wearing only light clothes and without shoes. In 
each subject, weight and height were measured to calcu-
late the BMI [weight (kg) divided by height squared (m2), 
kg/m2]. Height was measured to the nearest 1 cm using a 
wall-mounted stadiometer. Body weight was determined 
to the nearest 50 g using a calibrated balance beam scale. 
Waist circumference (WC) was measured to the clos-
est 0.1 cm using a non-stretchable measuring tape at the 
natural indentation or at a midway level between lower 
edge of the rib cage and iliac crest if no natural inden-
tation was visible. The measurement was made with the 
subject standing upright, feet together and arms hanging 
freely at the sides, without compression of the soft tissue. 
According to the National Cholesterol Education Pro-
gram’s Adult Treatment Panel III (NCEP-ATP III) crite-
ria, abdominal obesity was defined as WC ≥102 cm.
Biochemical measurements
Samples were collected in study population between 
8 and 10 a.m. after an overnight fast of at least 8 h and 
stored at −80 °C until processed. All biochemical analy-
ses including fasting plasma glucose, total cholesterol, 
triglycerides, aspartate aminotransferase (AST), alanine 
transaminase (ALT), γ-glutamyltransferase (γGT) were 
performed with a Roche Modular Analytics System in 
the Central Biochemistry Laboratory of our Institution. 
Low-density lipoprotein (LDL) and high-density lipo-
protein (HDL) cholesterol were determined by direct 
method (homogeneous enzymatic assay for the direct 
quantitative determination of LDL and HDL choles-
terol). C-Reactive Protein (CRP) levels were determined 
with a nephelometric assay with CardioPhase high-sen-
sitive from Siemens Healthcare Diagnostics (Marburg, 
Germany). Fasting insulin levels were measured by a 
solid-phase chemiluminescent enzyme immunoassay 
using a commercially available kits (Immunolite Diag-
nostic Products Co, Los Angeles, CA). The intra-assay 
coefficients of variations (CV) were <4  % for CRP and 
<5.5  % for insulin. HoMA-IR was calculated according 
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to Matthews et al. [22]: a value of HoMA-IR >2.0 was set 
as stringent measure of insulin resistance. VAI score was 
calculated using the following gender-specific formula, 
males [23]: [(WC/39.68)  +  (1.88  ×  BMI)  ×  (triglyc-
erides mg/dl  ×  0.0113/1.03)  ×  (1.31/HDL cholesterol 
mg/dl  ×  0.0259)]. The median 4.9 value was used as 
cut-off value [24]. FLI was calculated with the formula: 
[FLI  =  eL/(1  +  eL)  ×  100, L  =  0.953  ×  loge triglycer-
ides + 0.139 BMI + 0.718 × logeγGT + 0.053 × WC − 
15.745]. FLI of 30 was considered as the cut-off value on 
the basis of Bedogni’s criterion [20].
Criteria to define metabolic syndrome
According to the NCEP ATP III definition, metabolic 
syndrome (MetS) is present if three or more of the fol-
lowing five criteria are met: waist circumference over 
102 cm (men), blood pressure over 130/85 mmHg, fast-
ing triglyceride level over 150 mg/dl, fasting high-density 
lipoprotein cholesterol level less than 40 mg/dl (men) and 
fasting glucose over 100 mg/dl [25]. Blood pressure was 
measured using a standard sphygmomanometer in the 
supine position, after a rest of at least 5 min.
Ultrasound evaluation
The presence of HS, commonly known as “bright liver”, 
was assessed with a US diagnostic system (Logiq P5, 
General Electric, Milan, Italy) with a 3.5-MHz convex 
probe. All the US determinations were made by the same 
trained operator. The intra-operator variability, as evalu-
ated in 20 subjects within 1 week from the first ultrasono-
graphic examination, showed an overall r value of 0.92 
(p  <  0.001). As previously validated [26], the presence/
severity of HS was defined by comparing the echogenic-
ity of the liver and of the kidney cortex: Grade 0 (absent): 
iso-echogenicity; Grade 1 (mild): diffuse and homogene-
ous hyper-echogenicity; Grade 2 (moderate): attenua-
tion of the ultrasonic beam rear; Grade 3 (severe): lack of 
diaphragm profile visualization. Technically, echo inten-
sity can be influenced by many factors, particularly gain 
intensity. To avoid confounding factors that could modify 
echo intensity and thus bias comparisons, mean bright-
ness levels of both liver and right kidney cortex were 
obtained on the same longitudinal sonographic plane.
Statistical analysis
Results are expressed as mean ±  SD or as median plus 
range according to variable distributions  evaluated by 
Kolmogorov–Smirnov test. To correct for skewed dis-
tributions, CRP levels and HoMA-IR values were loga-
rithmically transformed and back-transformed for 
presentation in tables. Differences between groups were 
analyzed by paired t test or Wilcoxon signed-rank test, 
when appropriate. The chi 2 (χ2) test was used to test the 
significance of differences in frequency distribution. In 
the group of psoriatic patients, the correlations between 
variables were performed using Pearson r or Spearman’s 
rho correlation coefficients. The presence of significant 
associations of the presence of MetS, as dependent vari-
able, with PASI score and MUFA in the psoriatic group 
was analyzed using logistic regression, and odds ratio 
(OR) and 95 % confidence interval (CI) were computed.
In addition, in the group of psoriatic patients, three 
multiple linear regression analysis models (stepwise 
method), expressed as r2, Beta (β) and t, with PASI score 
as dependent variables were used to estimate the predic-
tive value of: (1) HoMA-IR, VAI and FLI; (2) complex and 
simple carbohydrates, total fat, MUFA and PUFA (n-6 
PUFA, n-3 PUFA and n-6/n-3 PUFAs ratio); (3) FLI and 
MUFA. In these analyses, we entered only those variables 
that had a p value <0.05 in the univariate analysis (partial 
correlation). To avoid multicollinearity, variables with a 
variance inflation factor (VIP) >10 were excluded. Values 
≤5 % were considered statistically significant. The power 
sample was calculated by the differences of means + SD 
of MUFA in each group. Data were stored and analyzed 
using the MedCalc® package (Version 12.3.0 1993–2012 
MedCalc Software bvba—MedCalc Software, Mari-
akerke, Belgium).
Results
With a type I (alpha) error, of 0.05 (95 %), and with a type 
II (beta) of 0.10, (90 %), the number of cases required for 
each group was set at 43, near to the ours. Socio-demo-
graphic, anthropometric and metabolic characteristics of 
the treatment-naïve patients with psoriasis and the sub-
jects matched for age and BMI serving as control group 
are shown in Table 1. Socio-demographic characteristics 
and participation in physical activity were not signifi-
cantly different in both groups, while the metabolic risk 
factors and liver function tests were significantly higher 
in psoriatic patients than in control group. In particu-
lar, logarithmically transformed CRP levels and HoMA-
IR in psoriatic patients were significantly higher than 
in controls [CRP: 0.1 (−2.3 − 3.4) vs −0.2 (−2.3 − 0.7), 
respectively; p  =  0.050; HoMA-IR: 1.0 (−1.2  −  2.7) vs 
−0.1 (−3.2  −  2.9), respectively; p  =  0.001]. CRP lev-
els and HoMA-IR values have been back-transformed 
for presentation in Table 1. HS was diagnosed in 95.1 % 
psoriatic patients (39 patients) vs 48.7  % controls (20 
subjects), χ2 =  19.578, p  <  0.001; in particular, grade 2 
and 3 HS was present in 25 psoriatic patients (60.8 %) vs 
10 controls (24.4 %), χ2 = 9.770, p = 0.002. In addition, 
HoMA-IR, VAI and FLI were also significantly higher 
in psoriatic patients. HoMA-IR values ≥2 occurred sig-
nificantly more frequently among case-patients than 
controls: 68.3  % (28 patients) vs 26.8  % (11 controls), 
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χ2 =  14.173, p  <  0.001. Similarly, VAI and FLI >cut-off 
values occurred significantly more frequently among 
psoriatic patients than controls: VAI: 95.1 % (39 patients) 
vs 75.6  % (31 controls), χ2  =  4.783, p  =  0.029; FLI: 
78.0 % (32 patients) vs 51.2 % (21 controls), χ2 = 5.335, 
p = 0.021. Table 2 shows the prevalence of the metabolic 
risk factors in the two groups. Although systolic/diastolic 
blood pressure values and fasting glucose levels were 
found to be higher among case-patients than controls, 
the prevalence of MetS was not statistically different in 
the two groups.
The total energy and nutrient intake in psoriatic 
patients and control group are reported in Fig. 1. All par-
ticipants to the study completed the 7-day food records. 
The dietary survey revealed that the psoriatic patients 
have a higher consumption of total and simple carbo-
hydrates, total fat, PUFA, n-6/n-3 PUFAs ratio, and 
cholesterol, while the consumption of protein, complex 
carbohydrates, MUFA, n-3 PUFA and fiber, is lower than 
in the control group. No statistically significant  differ-
ences of a total energy, SFA and n-6 PUFA were observed 
between  the two  groups. However, when the psoriatic 
patients were divided in two groups based on median 
percentage of MUFA intake (18.2  %), patients with low 
MUFA intake presented higher values of PASI score 
and CRP levels than their pairs with high MUFA intake 
(Fig. 2).
Correlation studies
Among psoriatic patients the mean value of PASI score 
was 9.0  ±  7.0 (range 0.1–28.3). Besides the negative 
correlation with HDL-cholesterol, PASI score directly 
correlated with anthropometric, metabolic and cardio-
metabolic parameters (Table 3). After adjusting for BMI, 
all the associations between PASI score and the study 
variables were preserved, except for AST. At multiple 
regression analysis, among HoMA-IR, VAI and FLI, the 
latter was the major predictor of PASI score (r2 = 0.358, 
β = 0.611, t = 4.823, p < 0.001).
In Table  4 is reported the correlation between PASI 
score, total energy and nutrient intake. PASI score cor-
related with all the dietary macronutrients, except for 
protein and total carbohydrates. After adjusting for BMI 
and number of parameters of Mets, the associations 
between PASI score and nutrient intake were mainly pre-
served. At logistic regression analysis between PASI score 
and MUFA, the MetS presence was well predicted only 
by higher PASI score (OR = 1.794; p = 0.002; CI 1.242–
2.591). At multiple regression analysis among macro-
nutrients, MUFA remained the major predictor of PASI 
score (r2 =  0.387, β = −0.635, t = −5.127, p  <  0.001). 
Finally, at multiple regression analysis, PASI score 
Table 1 Socio-demographic, anthropometric and  meta-
bolic characteristics of  psoriatic patients and  control 
group
The psoriatic patients exhibited statistically significant differences compared 
with controls for anthropometric measurements, metabolic profiles and 
cardio-metabolic indices. Results are expressed as mean ± SD or as median plus 
range according to variable distributions evaluated by Kolmogorov–Smirnov 
test. *CRP levels and *HoMA-IR values were logarithmically transformed and 
back-transformed for presentation in table. Differences between groups were 
analyzed by paired t test or Wilcoxon signed-rank test, when appropriate. The 
Chi-square (χ2) test was used to test the significance of differences between the 
two groups. Italicized p-values represent significant differences at p < 0.05
BMI Body Mass Index, SBP systolic blood pressure, DBP diastolic blood 
pressure, WC Waist Circumference, CRP C-reactive protein, HDL High-density 
lipoprotein, LDL low-density lipoprotein, AST aspartate aminotransferase, ALT 
Alanine transaminase, γGT γ-glutamyltransferase, HoMA-IR Homeostatic Model 
Assessment for Insulin Resistance, VAI Visceral Adiposity Index, FLI Fatty Liver 
Index, MetS Metabolic Syndrome
Parameters Psoriatic patients
n = 41
Control group
n = 41
p values
Age (years) 52.1 ± 11.1 49.7 ± 10.0 0.309
BMI (kg/m2) 31.2 ± 4.4 30.1 ± 6.9 0.407
Education status χ2 = 0.049
p = 0.825
 Graduates (n) 20 22
 Higher second-
ary (n)
21 19
Employment χ2 = 1.384
p = 0.239
 Un-employed (n) 3 0
 Employed (n) 38 41
Marital status χ2 = 0.139
p = 0.710
 Single (n) 5 3
 Married (n) 36 38
Physical activity χ2 = 0.625
p = 0.429
 Sedentary (n) 39 36
 Moderate (n) 2 5
SBP (mmHg) 126.7 ± 15.0 116.6 ± 11.8 0.002
DBP (mmHg) 80.0 ± 9.7 71.3 ± 5.7 <0.001
WC (cm) 108.1 ± 13.8 102.6 ± 8.4 0.035
CRP levels (ng/ml)* 3.7 ± 6.4 0.8 ± 0.5 0.050
Fasting Glucose  
(mg/dl)
111.7 ± 34.2 87.9 ± 32.8 0.004
Insulin (μU/ml) 11.1 ± 6.2 7.4 ± 7.6 0.022
Total cholesterol 
(mg/dl)
219.0 ± 44.5 199.2 ± 47.9 0.021
HDL cholesterol 
(mg/dl)
38.9 ± 11.8 45.3 ± 11.9 0.025
LDL cholesterol  
(mg/dl)
147.3 ± 49.0 124.4 ± 49.2 0.035
Triglycerides (mg/ml) 164.4 ± 93.5 127.4 ± 48.8 0.041
AST (U/l) 32.4 ± 15.5 31.9 ± 22.9 0.932
ALT (U/l) 37.3 ± 17.0 26.3 ± 12.0 0.007
γGT (U/l) 43.8 ± 23.8 31.3 ± 20.9 0.030
HoMA-IR* 3.4 ± 2.9 2.0 ± 3.3 0.001
VAI 5.4 (1.3–23.6) 4.1 (1.1–8.6) 0.049
FLI 76.1 ± 23.6 60.4 ± 26.9 0.009
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was better predicted by MUFA than FLI (r2  =  0.387, 
β  =  −0.635, t  =  −5.127, p  <  0.001 vs r2  =  0.532, 
β = 0.426, t = 3.619, p = 0.001).
Discussion
The main result of this study indicates that psoriatic 
patients, compared to the control group, have a higher 
Table 2 Frequency of metabolic risk factors in psoriatic patients and control group
The psoriatic patients exhibited statistically significant differences compared with controls for systolic and diastolic blood pressure and fasting glucose. According  
to the NCEP ATP III definition, the metabolic syndrome is defined as the coexistence of three or more of the following findings: (1) Increased waist circumference. 
(2) Hypertriglyceridaemia. (3) Hypertension. (4) Elevated fasting plasma glucose. (5) Low high-density lipoprotein (HDL) cholesterol level. Results are 
expressed as number and percentage. The Chi square (χ2) test was used to test the significance of differences between the two groups. Italicized p-values 
represent significant differences at p < 0.05
WC Waist Circumference, SBP systolic blood pressure, DBP diastolic blood pressure, HDL High-density lipoprotein, MetS Metabolic Syndrome
Parameters Psoriatic patients
n = 41
Control group
n = 41
χ2 p values
n % n %
WC (≥102 cm) 27 65.9 21 51.2 1.26 0.262
SBP/DBP (≥130/85 mmHg) 17 41.5 7 17.1 4.77 0.029
Triglycerides (≥150 mg/dl) 17 41.5 16 39.0 0.00 1.000
HDL cholesterol (≤40 mg/dl) 16 39.0 10 24.4 1.41 0.235
Fasting glucose (≥100 mg/dl) 26 63.4 13 31.7 7.04 0.008
MetS diagnosis 17 41.1 9 22.0 2.76 0.097
Fig. 1 Dietary pattern in psoriatic patients and control group. In the figure are shown the dietary differences between psoriatic patients and con-
trol subjects. a Total calories (kcal). b Percentage of macronutrients in diet. Panel C Carbohydrates (CHO) (% of total charbohydrates) and fibers (g/
day). d Fats (SFA saturated fatty acids; MUFA monounsaturated fatty acids; PUFA polyunsaturated fatty acids.). e Cholesterol. Psoriatic patients have 
a higher consumption of total and simple carbohydrates, total fat, PUFA, n-6/n-3 PUFAs ratio, and cholesterol, while the consumption of protein, 
complex carbohydrates, MUFA, n-3 PUFA and fiber, is lower than in the control group. No statistically significant differences of a total energy, SFA 
and n-6 PUFA were observed between the two groups
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consumption of simple carbohydrates, total fat and n-6/
n-3 PUFAs ratio, with a lower intake of protein, complex 
carbohydrates, MUFA, n-3 PUFA and fiber. In addition, 
psoriatic patients have elevated HoMA-IR, VAI and 
higher prevalence both of MetS and HS, as evidenced 
by liver ultrasound and higher FLI values. These find-
ings are in line with the current literature on the asso-
ciation between psoriasis and fatty liver in non-alcoholic 
fatty liver disease (NAFLD) and could be explained by 
the inflammatory burden of psoriasis acting on fatty 
liver development also independently of the metabolic 
derangements commonly reported among psoriatic 
patients [27, 28].
In the group of psoriatic patients we have further inves-
tigated the association between nutrition and psoriasis by 
correlating dietary macronutrient intake, clinical severity 
of psoriasis and altered cardio-metabolic profile. In par-
ticular, also adjusting for BMI and MetS, the correlations 
between PASI score and nutrient intake were mainly pre-
served. Our study is the first evidence reporting that in 
psoriatic patients the high consumption of simple car-
bohydrates is associated with the clinical severity of the 
disease.
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Fig. 2 PASI score and CRP levels in psoriatic patients on the basis of 
MUFA intake. Psoriatic patients were divided in two groups on the 
basis of median percentage of MUFA intake (18.2 %). Patients with 
MUFA intake below median (Low-MUFA) presented higher values 
of PASI score and CRP levels when compared with patients having a 
MUFA intake higher than the median (High-MUFA). PASI Psoriasis Area 
and Severity Index,  CRP C-reactive protein
Table 3 Correlations among PASI score and study variable 
in psoriatic patients
At simple correlation, PASI score was significantly association with BMI, WC, 
CRP levels, metabolic profile, liver function tests, and the cardio-metabolic 
indices. After adjusting for BMI the associations between PASI score and the 
study variables were mainly preserved. Correlations between variables were 
performed using Pearson r and Spearman’s rho correlation coefficients. Italicized 
p-values represent significant differences at p < 0.05
BMI Body Mass Index, SBP systolic blood pressure, DBP diastolic blood 
pressure, WC Waist Circumference, CRP C-reactive protein, HDL High-density 
lipoprotein, LDL low-density lipoprotein, AST aspartate aminotransferase, ALT 
Alanine transaminase, γGT γ-glutamyltransferase, HoMA-IR Homeostatic Model 
Assessment for Insulin Resistance, VAI Visceral Adiposity Index, FLI Fatty Liver 
Index, HS Hepatic Steatosis, MetS Metabolic Syndrome
Simple correlation Partial correlation 
(adjusting for BMI)
Parameters PASI score p values PASI score p values
Age (years) −0.151 0.347 −0.095 0.560
BMI (kg/m2) 0.532 <0.001 – –
SBP (mmHg) 0.883 <0.001 0.906 <0.001
DBP (mmHg) 0.716 <0.001 0.808 <0.001
WC (cm) 0.736 <0.001 0.613 <0.001
CRP levels (ng/ml) 0.427 0.005 0.345 0.029
Fasting Glucose (mg/dl) 0.471 0.002 0.502 0.001
Insulin (μU/ml) 0.409 0.008 0.466 0.002
Total cholesterol (mg/dl) −0.123 0.444 −0.133 0.412
HDL cholesterol (mg/dl) −0.528 <0.001 −0.514 0.001
LDL cholesterol (mg/dl) −0.145 0.367 −0.136 0.402
Triglycerides (mg/ml) 0.420 0.006 0.367 0.020
AST (U/l) 0.313 0.046 0.223 0.167
ALT (U/l) 0.498 0.001 0.411 0.009
γGT (U/l) 0.516 0.001 0.476 0.002
HoMA-IR 0.485 0.001 0.492 0.001
VAI 0.580 <0.001 0.544 <0.001
FLI 0.611 <0.001 0.373 0.018
HS 0.388 0.012 0.311 0.050
MetS (n. of parameters) 0.758 <0.001 0.683 <0.001
Table 4 Correlation between  PASI score with  energy 
and nutrient intake
PASI score well correlated with all the dietary components, except for protein 
and total carbohydrates. Correlations between variables were performed using 
Pearson r and Spearman’s rho correlation coefficients. After adjusting for BMI 
and number of parameters of metabolic syndrome, the associations between 
PASI score and nutrient intake were mainly preserved. Italicized p-values 
represent significant differences at p < 0.05
SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA 
polyunsaturated fatty acids
Simple correlation Partial correla-
tion (adjusting 
for BMI and met-
abolic syndrome)
Parameters PASI score PASI score
r p values r p values
Total energy (kcal) 0.432 0.005 0.022 0.895
Protein (% of total kcal) −0.083 0.604 0.006 0.972
Carbohydrate (% of total kcal) −0.164 0.305 −0.188 0.251
Complex (% of total kcal) −0.471 0.002 −0.357 0.026
Simple (% of total kcal) 0.564 <0.001 0.352 0.028
Fat (% of total kcal) 0.491 0.001 0.372 0.020
SFA (% of total kcal) 0.413 0.007 0.289 0.075
MUFA (% of total kcal) −0.635 <0.001 −0.460 0.003
PUFA (% of total kcal) 0.523 <0.001 0.384 0.016
n-6 PUFA (g/day) 0.514 0.001 0.321 0.047
n-3 PUFA (g/day) −0.505 0.001 −0.547 <0.001
n-6/n-3 PUFAs ratio 0.621 <0.001 0.532 <0.001
Cholesterol (mg/day) 0.443 0.004 0.112 0.498
Fiber (g/day) −0.471 0.002 −0.115 0.487
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Single food components have been suggested to play a 
role in etiology and pathogenesis of psoriasis [29]. Previ-
ous studies on the relationship of diet and nutrition with 
psoriasis have focused on either individual nutrients (e.g. 
fish oil, n-3 PUFA, vitamin B12, vitamin D, vitamin A, 
selenium, inositol and zinc and antioxidants) or individ-
ual food groups (e.g. fruit, vegetables, and fish [30]. How-
ever, diet is a complex combination of foods from various 
groups and nutrients, and some nutrients are highly cor-
related, thus it is very challenging, in free-living popula-
tions, to separate the effect of a single nutrient or food 
group from others [31]. In addition, it is well known that 
gender, age and educational status influence food choice 
behaviors [7]. In particular, women’s dietary profiles is 
characterized by a higher carbohydrates intake, includ-
ing fruit and vegetables [8]. In the extensive survey on 
dietary intake and nutritional status in psoriatic patients 
of both gender using the 2003–2006 NHANES data [11], 
it has been shown an association between psoriasis and 
lower intake of simple carbohydrates. This association 
was largely unexpected and in contrast with literature’s 
data indicating an association between psoriasis, insulin 
resistance and type 2 diabetes [32, 33].
Apart from reasonable differences in ethnic origins and 
eating style, methodological differences might account 
for the apparent contrast in the association between 
carbohydrate intake and clinical severity of psoriasis 
reported in our study with that observed by Johnson et al. 
[11]. In particular, in our study, the nutritional status was 
evaluated using the 7-day food records, the effect of gen-
der-specific food choice and the possible interference of 
the anti-psoriatic agents on metabolic profile were con-
trolled by  including only male treatment-naïve patients; 
furthermore, the diagnosis of psoriasis was clinically 
evaluated by PASI score and not self-reported.
A growing body of evidence indicates a common 
immune profile between psoriasis and MetS acting 
through increased Th type 1 proinflammatory cytokines 
[34]. Besides the well-known positive correlation between 
the clinical severity of psoriasis and MetS [1, 10], insulin 
resistance [32], and HS [2], we demonstrated also a novel 
association of PASI score with VAI and FLI, two surro-
gate indices of cardio-metabolic risk strictly correlated 
with MetS. This study demonstrates that the association 
between PASI and FLI is more significant than that with 
liver ultrasound. In particular, among HoMA-IR, VAI 
and FLI, the latter is the main predictor of the clinical 
severity of psoriasis. The novel association of the clini-
cal severity of psoriasis with VAI and FLI supports the 
hypothesis of an early involvement in the inflammation 
milieu of psoriatic patients of other non-classical risk fac-
tors, i.e. HS and altered production of adipocytokines by 
dysfunctional adipocytes. According to these data, VAI 
and FLI can be suggested as early markers of the cardio-
metabolic risk profile of psoriatic patients.
In our study, we found that the lowest intake of MUFA 
was the main predictor of the highest PASI score. The 
association between low MUFA consumption and pro-
gression of psoriasis is in line with the same observation 
reported in other chronic inflammatory diseases [16, 17]. 
MUFA are considered a healthy dietary fat, as opposed 
to SFA. The most frequently consumed MUFA rich die-
tary oils is EVOO. Traditionally, the beneficial effects of 
EVOO have been attributed to its high MUFA content 
(oleic acid) as it protects lipoproteins and cellular mem-
branes from oxidative damage [35]. A low consumption 
of MUFA is a well-known mechanism contributing to the 
pathogenesis of Mets [36] and NAFLD in general popu-
lation [37]. Besides their anti-oxidant and anti-inflam-
matory bioactive properties, MUFA may exert their 
beneficial effects on the pathogenesis of NAFLD through 
their influence on lipid metabolism either in the liver or 
the abdominal adipose tissue. In particular, a high-MUFA 
diet may avoid fat deposition in liver by the activation 
of catabolic pathways and could favor fatty acid deposi-
tion in adipose tissue enhancing the clearance of circu-
lating triglyceride-rich lipoproteins by lipoprotein lipase 
[38, 39]. In this study, psoriatic patients presented lower 
MUFA consumption, worse lipid profile, and higher VAI 
score compared with their BMI-matched pairs. Moreo-
ver, the psoriatic patients with the lowest MUFA intake 
presented the highest values of PASI score and CRP 
levels. Of interest, in our group of psoriatic patients 
the association between psoriasis and metabolic syn-
drome appears to be independent of MUFA intake. In 
this respect, it is possible to speculate that the associa-
tion of the low MUFA intake with the clinical severity of 
psoriasis might be based on the its adjunctive effect into 
increase the inflammation milieu of psoriatic patients, 
acting also independently of MetS, likely through the 
involvement of other non-classical risk factors, i.e. 
HS, expressed by FLI, and dysfunctional adipocytes, 
expressed by VAI.
We are aware that there are some limitations in the 
current study. First, the research suffers from a selec-
tion bias being limited to males subject only. This choice 
has been determined on the basis of the gender differ-
ences in the food pattern choices and in the anthro-
pometric measures. Second, the sample size is small 
and a larger group of patients would have been more 
informative. However, in order to improve the power 
of the study, we increased the homogeneity of the stud-
ied group by including only treatment-naïve adult male 
patients, while treated patients were excluded to avoid 
the possible interference of the anti-psoriatic agents on 
metabolic profile. In addition, the diagnosis of psoriasis 
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was not self-reported, but clinically evaluated using the 
PASI score. Finally, VAI and FLI are surrogate of adipo-
cyte dysfunction and HS, respectively, but the reliabil-
ity of FLI is not completely accepted by all researches. 
Nevertheless, the main strength of this study is the use 
of the 7-day food records. This method, which is con-
sidered as the “gold standard” in validation studies of 
different types of self-administered food frequency ques-
tionnaires, allows a more accurate measurement of the 
real dietary and macronutrient intakes compared to 
those obtained by retrospective food frequency ques-
tionnaires [40, 41].
Conclusions
In conclusion, differences in macronutrient intake are 
present in adult male psoriatic patients compared to 
the control group. In the psoriatic patients, these dif-
ferences are associated with the clinical severity of the 
disease and cardio-metabolic risk. Among cardio-met-
abolic indices, FLI, an accurate predictor of the HS, the 
hepatic manifestation of metabolic syndrome, might 
represent an early indicator of the cardio-metabolic risk 
profile of psoriatic patients. The low consumption of 
MUFA is the main predictor of the clinical severity of 
psoriasis and might act as a possible adjunctive mecha-
nism in increasing the inflammation milieu of psoriatic 
patients, also independently of MetS. These results sug-
gest a central role of Nutritionists in the management of 
psoriatic patients.
Future observational studies on larger population sam-
ples, comparing female and male psoriatic patients and 
long-term dietary intervention trials, will be critical for 
elucidate the global effects of macronutrient intake in 
psoriasis pathogenesis and progression.
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